1.	Doxorubicin Hydrochloride Liposome or Capecitabine as First-Line Chemotherapy in Treating Women With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
2.	A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO# 08-1373, NCT00900744
3.	Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-09-14B, NCT00984269
4.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
5.	Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP9881B/3001, NCT00081796
6.	Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
7.	Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: SWOG-S0500, S0500, CALGB-SWOG-S0500, NCT00382018
8.	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
9.	Regional Anesthesia and Breast Cancer Recurrence Phase: Phase III Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 06-692, NCT00418457
10.	Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG108838, NCT00558103
11.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
12.	A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR014764, NCT00580112
13.	Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40503, CALGB 40503, NCT00601900
14.	Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/neu-Positive Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
15.	Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP12-0606, TRI0-CIRG-012, TRI0-012, EUDRACT Number: 2008-001727-65, NCT00703326
16.	Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
17.	Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
18.	A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI BRE 145, TITAN, NCT00789581
19.	An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
20.	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111438, NCT00820222
21.	Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-70604, CALGB 70604, NCT00869206
22.	Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001Y2301, EUDRACT Number: 2008-008698-69, NCT00863655
23.	Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, EUDRACT Number: 2008-006556-21, NCT00876395
24.	A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: NSABP B-46-I, USOR 07132, NCT00887536
25.	Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3005, NCT00915018